Imlab SRL
1.2 FTEThe score of Imlab shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +27 % Total assets +1 % Headcount (avg FTE) +20 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Imlab's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 55,904 € | ||||
| Equity | 565,492 € | ||||
| Cash | 109,637 € | ||||
| EBITDA | 116,091 € | ||||
| Total assets | 767,272 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Jul 2026
- Year ended 31 Dec 2024filed on 24 Jul 2025
- Year ended 31 Dec 2023filed on 24 Jun 2024
- Year ended 31 Dec 2022filed on 19 Jul 2023
- Year ended 31 Dec 2021filed on 31 Aug 2022
Imlab's financial analysis
- Solvency73.7%sector median: 46.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Imlab
Imlab's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0466.721.339
- VAT number
- BE0466721339
- Peppol
- Registered · 0208:0466721339 · as of 09 Nov 2026
- Legal form
- SRL
- Incorporated
- 23 Aug 1999
- Registered office
- 3384 Glabbeek
- Size
- Micro · 1.2 FTE
- Latest accounts
- 2025 · filed on 31 Jul 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Imlab (SRL) has been based in Glabbeek since 1999, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net profit of 55,904 € and equity of 565,492 €; its revenue is not published. With 1.2 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 73.7%, above the median of its sector (46.0%).
Companies similar to Imlab
Companies in the same business, of comparable size and area, outside its group.
- MMM Benelux Wholesale of pharmaceutical and medical goods Tienen · balance sheet €2.72m
- Endovision Wholesale of pharmaceutical and medical goods Holsbeek · balance sheet 669,623 €
- Odontos Handel BE Wholesale of pharmaceutical and medical goods Temse · balance sheet 779,265 €
- ProCare België Wholesale of pharmaceutical and medical goods Leuven · balance sheet 730,333 €
- W M Hopital (B) Wholesale of pharmaceutical and medical goods Mont-de-l'Enclus · balance sheet 683,247 €
- Farla Medical Wholesale of pharmaceutical and medical goods Antwerp · balance sheet 895,466 €
- Tendim Wholesale of pharmaceutical and medical goods Duffel · balance sheet 953,104 €
- Prime Medical Solutions Wholesale of pharmaceutical and medical goods Hasselt · balance sheet 975,003 €
Frequently asked questions about Imlab
What is the revenue of Imlab?
Imlab files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Imlab?
In Belgium, the VAT number is the company number prefixed with BE: BE0466721339 for Imlab, if the company is VAT-registered. Its company number (CBE) is 0466.721.339.
Where is the registered office of Imlab?
According to the CBE register, the registered office of Imlab is in 3384 Glabbeek.
What is the equity of Imlab?
At the close of the 2025 financial year, the equity of Imlab amounts to 565,492 €, a solvency of 73.7% of total assets.
How many people work at Imlab?
1.2 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Imlab?
The register lists 2 active mandates at Imlab. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Imlab
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →